HUP0400588A2 - A von Willebrand faktort (vWF) hasító proteáz polipeptid, a polipeptidet kódoló nukleinsav, és a polipeptid használata - Google Patents

A von Willebrand faktort (vWF) hasító proteáz polipeptid, a polipeptidet kódoló nukleinsav, és a polipeptid használata

Info

Publication number
HUP0400588A2
HUP0400588A2 HU0400588A HUP0400588A HUP0400588A2 HU P0400588 A2 HUP0400588 A2 HU P0400588A2 HU 0400588 A HU0400588 A HU 0400588A HU P0400588 A HUP0400588 A HU P0400588A HU P0400588 A2 HUP0400588 A2 HU P0400588A2
Authority
HU
Hungary
Prior art keywords
polypeptide
von willebrand
willebrand factor
vwf
nucleic acid
Prior art date
Application number
HU0400588A
Other languages
English (en)
Inventor
Gerhard Antoine
Miha Furlan
Helena Elisabeth Gerritsen
Randolf Kerschbaumer
Bernhard Laemmle
Friedrich Scheiflinger
Hans-Peter Schwarz
Luigina Tagliavacca
Peter Turecek
Dirk Voelkel
Klaus Zimmermann
Original Assignee
Baxter Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27110398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0400588(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Aktiengesellschaft filed Critical Baxter Aktiengesellschaft
Publication of HUP0400588A2 publication Critical patent/HUP0400588A2/hu
Publication of HUP0400588A3 publication Critical patent/HUP0400588A3/hu
Publication of HU227996B1 publication Critical patent/HU227996B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/6416—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A találmány tárgya egy von Willebrand faktort hasító proteáz (vWF-cp)polipeptid, a vWF-cp polipeptid aminosav szekvenciáját kódolónukleinsav molekula, valamint a polipeptidet tartalmazó készítmény. Atalálmány tárgya továbbá a von Willebrand faktort hasító proteázpolipeptid alkalmazása von Willebrand faktort hasító proteázpolipeptidhez kötő molekulák előállítására, és a trombózis valaminttromboembóliás betegség profilaxisában és kezelésében használhatókészítmény előállításában. Ó
HU0400588A 2000-11-22 2001-11-20 A von Willebrand faktort (vWF) hasító proteáz polipeptid, a polipeptidet kódoló nukleinsav, és a polipeptid használata HU227996B1 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72125400A 2000-11-22 2000-11-22
US09/833,328 US6926894B2 (en) 2000-11-22 2001-04-12 Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
PCT/EP2001/013391 WO2002042441A2 (en) 2000-11-22 2001-11-20 VON WILLEBRAND FACTOR (vWF) CLEAVING PROTEASE POLYPEPTIDE, NUCLEIC ACID ENCODING THE POLYPEPTIDE AND USE OF POLYPEPTIDE

Publications (3)

Publication Number Publication Date
HUP0400588A2 true HUP0400588A2 (hu) 2004-06-28
HUP0400588A3 HUP0400588A3 (en) 2006-01-30
HU227996B1 HU227996B1 (hu) 2012-08-28

Family

ID=27110398

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400588A HU227996B1 (hu) 2000-11-22 2001-11-20 A von Willebrand faktort (vWF) hasító proteáz polipeptid, a polipeptidet kódoló nukleinsav, és a polipeptid használata

Country Status (15)

Country Link
US (7) US6926894B2 (hu)
EP (1) EP1346034B1 (hu)
AT (1) ATE423194T1 (hu)
AU (1) AU2002218306A1 (hu)
CZ (1) CZ305602B6 (hu)
DE (1) DE60137710D1 (hu)
DK (1) DK1346034T3 (hu)
ES (1) ES2322126T3 (hu)
HU (1) HU227996B1 (hu)
NZ (1) NZ526616A (hu)
PT (1) PT1346034E (hu)
RU (1) RU2003118441A (hu)
SI (1) SI1346034T1 (hu)
SK (1) SK288119B6 (hu)
WO (1) WO2002042441A2 (hu)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6926894B2 (en) * 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
JP2003284570A (ja) * 2001-04-25 2003-10-07 Chemo Sero Therapeut Res Inst フォンビルブラント因子（ｖＷＦ）切断酵素
WO2003016492A2 (en) * 2001-08-16 2003-02-27 The Regents Of The University Of Michigan Adamts13 genes and proteins and variants, and uses thereof
DE20213920U1 (de) 2002-07-03 2003-01-16 Boehm Martina Diagnostikum zum Nachweis der den von Willebrand-Faktorspaltenden Aktivität von ADAMTS13
AU2012203101B2 (en) * 2002-09-25 2014-10-02 Km Biologics Co., Ltd. Antibody against enzyme specifically cleaving von villebrand factor and assay system using the same
DE60331666D1 (de) * 2002-09-25 2010-04-22 Chemo Sero Therapeut Res Inst Antikörper gegen ein den von-willebrand-faktor spezifisch spaltendes enzym und assay-system unter verwendung davon
US20040185042A1 (en) * 2003-03-20 2004-09-23 Friedrich Scheiflinger Immunoadsorption of anti-von Willebrand Factor cleaving protease antibodies
US7763430B2 (en) * 2003-04-22 2010-07-27 Baxter International Inc. Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies
US8088624B2 (en) 2003-12-22 2012-01-03 Mitsubishi Kagaku Iatron, Inc. Method of detecting thrombosis by measuring von Willenbrand factor-cleaving protease
EP1568782A1 (de) * 2004-02-25 2005-08-31 Clemens Bockmeyer Diagnose und Therapie von ADAMTS-13 assoziierten Erkrankungen
US20080138837A1 (en) * 2004-07-19 2008-06-12 Robert Greenfield Methods and kits for detecting and measuring ADAMTS13/FXI complexes
ATE468536T1 (de) * 2004-07-19 2010-06-15 American Diagnostica Inc Verfahren zur messung von adamts13-aktivität auf der blutplättchenoberfläche.
US7270976B2 (en) * 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
PL1902141T3 (pl) 2005-06-17 2012-12-31 Baxalta Inc Kompozycje o działaniu trombolitycznym zawierające ADAMTS13
US7893616B2 (en) * 2006-02-27 2011-02-22 Ohio State University Process to determine enzyme activity
FR2918375B1 (fr) * 2007-07-05 2009-10-16 Lab Francais Du Fractionnement Utilisation d'un support de chromatographie pour reduire la quantite d'adamts13 dans une solution derivee du plasma
PT2235197T (pt) 2007-12-27 2017-10-11 Baxalta Inc Processos para cultura de células
KR101573972B1 (ko) 2009-07-31 2015-12-02 백스터 인터내셔널 인코포레이티드 Ａｄａｍｔｓ 단백질 발현을 위한 세포 배양 배지
US8945895B2 (en) 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
CN102573792B (zh) 2009-09-21 2014-10-15 巴克斯特国际公司 稳定化的液体和冻干的adamts13制剂
CN103097409A (zh) 2010-07-08 2013-05-08 巴克斯特国际公司 在细胞培养物中生产重组高分子量vWF的方法
SG191186A1 (en) 2010-12-15 2013-07-31 Baxter Int Eluate collection using conductivity gradient
JP2014517294A (ja) 2011-05-19 2014-07-17 バクスター・インターナショナル・インコーポレイテッド 循環ａｄａｍｔｓ１３抗体複合体の検出
KR102006151B1 (ko) 2012-11-27 2019-10-10 삼성디스플레이 주식회사 터치를 인식하고 전기 촉각 자극을 제공하는 표시 장치 및 그 구동 방법
AU2013203062C1 (en) 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13
US10639307B2 (en) * 2015-05-15 2020-05-05 Children's Medical Center Corporation Methods relating to the diagnosis and treatment of preeclampsia comprising administration of ADAMTS13 polypeptides
EA201990373A1 (ru) 2016-08-04 2019-07-31 Баксалта Инкорпорэйтед Применение adamts13 для лечения, уменьшения интенсивности и/или предупреждения вазоокклюзивного криза при серповидноклеточной анемии, остром повреждении легкого и/или остром респираторном дистресс-синдроме
FR3069156B1 (fr) * 2017-07-21 2019-08-09 Universite de Bordeaux Clusterine pour son utilisation dans le traitement des micro-angiopathies thrombotiques
JP2023521658A (ja) 2020-04-02 2023-05-25 武田薬品工業株式会社 Ａｄａｍｔｓ１３バリアント、組成物、及びその使用
US20230201319A1 (en) 2020-05-22 2023-06-29 Takeda Pharmaceutical Company Limited Adamts13 compositions and methods for treating and diagnosing complications of coronavirus disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6068838A (en) * 1996-04-29 2000-05-30 Baxter Aktiengesellschaft Purified multimerase
AT406867B (de) * 1997-02-27 2000-10-25 Immuno Ag Verfahren zur gewinnung von hochreinem vwf oder faktor viii/vwf-komplex
US20010049106A1 (en) * 2000-04-27 2001-12-06 Leonard Buckbinder ADAMTS polypeptides, nucleic acids encoding them, and uses thereof
US6926894B2 (en) * 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
US7070532B2 (en) * 2003-08-26 2006-07-04 General Motors Corporation Planetary transmission having a rotating-type torque-transmitting mechanism with a stationary piston

Also Published As

Publication number Publication date
DE60137710D1 (de) 2009-04-02
SK288119B6 (sk) 2013-09-03
DK1346034T3 (da) 2009-05-11
RU2003118441A (ru) 2004-12-10
EP1346034A2 (en) 2003-09-24
US20140335071A1 (en) 2014-11-13
US20050266528A1 (en) 2005-12-01
US7910094B2 (en) 2011-03-22
CZ20031718A3 (cs) 2004-07-14
NZ526616A (en) 2005-04-29
HUP0400588A3 (en) 2006-01-30
US8703429B2 (en) 2014-04-22
US20020136713A1 (en) 2002-09-26
WO2002042441A3 (en) 2002-08-08
US20090017467A1 (en) 2009-01-15
US6926894B2 (en) 2005-08-09
ES2322126T3 (es) 2009-06-17
US8703426B2 (en) 2014-04-22
HU227996B1 (hu) 2012-08-28
WO2002042441A2 (en) 2002-05-30
SK8022003A3 (en) 2004-04-06
US20090203110A1 (en) 2009-08-13
US9309506B2 (en) 2016-04-12
US20170065686A1 (en) 2017-03-09
SI1346034T1 (sl) 2009-08-31
AU2002218306A1 (en) 2002-06-03
US7501117B2 (en) 2009-03-10
EP1346034B1 (en) 2009-02-18
CZ305602B6 (cs) 2016-01-06
US20080176312A1 (en) 2008-07-24
PT1346034E (pt) 2009-05-05
ATE423194T1 (de) 2009-03-15

Similar Documents

Publication Publication Date Title
HUP0400588A2 (hu) A von Willebrand faktort (vWF) hasító proteáz polipeptid, a polipeptidet kódoló nukleinsav, és a polipeptid használata
HUP0500058A2 (hu) Új alkalikus proteáz változatok és ezeket tartalmazó mosó- és tisztítószerek
HUP0303246A2 (hu) Aktív fehérjék fokozott kinyerése
NO952989D0 (no) Fremgangsmåte til refolding av proteiner
DK1385943T3 (da) Nye varianter af alkalisk protease og vaskemidler og rengöringsmidler indeholdende disse nye varianter af alkalisk protease
HUP0402162A2 (hu) A humán angiopoietin-2 specifikus kötőanyagai
DK1434789T3 (da) Forbedret proteindisaggregering og refoldning under tryk
DE69226182D1 (de) Stabilisierte enzyme und waschmittelzusammensetzungen
HUP0303854A2 (hu) Szintetikus erythropoiesis-stimuláló proteinek
HUP0300299A2 (hu) Szabad aminosavakat tartalmazó kompozíció
BRPI0519172A2 (pt) proteÍna mutante, polinucleotÍdeo, microorganismo transformado, e, mÉtodos de produzir uma proteÍna mutante, um peptÍdeo, e alfa-l-aspartil-l-fenilalanina-beta-Éster, e de projetar e produzir uma proteÍna mutante
DE50214734D1 (de) Oligo- oder polyalkylenglycolgekoppelte thrombininhibitoren
DE69435277D1 (de) Klonierung und rekombinante Herstellung von Phospholipase aus Vespidae und immunologische Therapien darauf basierend
ATE486915T1 (de) Azeotrop-ähnliche zusammensetzung von 1,2-dichlor-3,3,3-trifluorpropen und fluorwasserstoff
Apitz-Castro et al. Purification and partial characterization of draculin, the anticoagulant factor present in the saliva of vampire bats (Desmodus rotundus)
EP1481061A4 (en) AGAINST DENATURING AGENTS STABLE AND / OR PROTEASERESISTENT, CHAPERONAL OLIGOMER PROTEINS, THESE CODING POLYNUCLEOTIDES AND THEIR USES
Fish et al. Routes of Thrombin Action in the Production of Proteolytically Modified, Secondary Forms of Antithrombin‐Thrombin Complex
AR023021A1 (es) Variante de una proteasa serina, gen de proteasa serina mutante qu lae codifica y composicion para cuidado personal
ATE150791T1 (de) Proteinstruktur des pflanzlichen toxins gelonin
NO972313L (no) Peptider som er i stand til å binde til GAP-protein-SH3-området, nukleotid-sekvenser som koder for dette samt fremstilling og bruk derav
Freato et al. Probing activation‐driven changes in coagulation factor IX by mass spectrometry
Gase et al. Functional significance of NH2-and COOH-terminal regions of staphylokinase in plasminogen activation
EE05296B1 (et) Glkuronl-C5-epimeraas, seda kodeeriv DNA ja selle kasutamine
AU2888702A (en) Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
EP1434483A4 (en) NUCLEIC ACID CODING, LINKED CHROMO / FLUORESCENT DOMAINS AND METHOD OF USE THEREOF

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: BAXALTA GMBH, CH

Free format text: FORMER OWNER(S): BAXTER AKTIENGESELLSCHAFT, AT

Owner name: BAXALTA INCORPORATED, US

Free format text: FORMER OWNER(S): BAXTER AKTIENGESELLSCHAFT, AT

FH91 Appointment of a representative

Free format text: FORMER REPRESENTATIVE(S): IFJ. SZENTPETERI ADAM, S.B.G. & K. SZABADALMI UEGYVIVOEI IRODA, HU

Representative=s name: SBGK SZABADALMI UEGYVIVOEI IRODA, HU